Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

• Gut microbiota composition is linked to the effectiveness of CAR T-cell therapy in myeloma patients, highlighting a potential biomarker.
• Taxonomic profiles of the gut microbiota were assessed in multiple myeloma patients before CAR T infusion, showing significant variation.
• Analysis of gut microbiota before lymphodepletion suggests its role in shaping metabolic and immune responses during therapy.
• Further investigation into microbiota may inform treatment strategies and improve efficacy of CAR T-cell therapy in myeloma.